<DOC>
	<DOC>NCT02699450</DOC>
	<brief_summary>This is a multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, three parallel group, 28-week study in participants with CI-DME. Only one eye will be selected as the study eye. Where both eyes meet all eligibility criteria, the eye with the worse best corrected visual acuity (BCVA) will be defined as the study eye. Participants will be randomized into each arm group (1:1:1) and total duration of the study will be approximately 32 weeks.</brief_summary>
	<brief_title>A Phase 2 Study of RO6867461 in Participants With Center-Involving Diabetic Macular Edema (CI-DME) (BOULEVARD)</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Macular edema associated with diabetic retinopathy (DR) Decreased visual activity (VA) attributable primarily to DME Diagnosis of diabetes mellitus (DM) Proliferative diabetic retinopathy (PDR) Cataract surgery within 3 months of Baseline, or any other previous intraocular surgery Uncontrolled glaucoma Current or history of ocular disease in the study eye other than DME Major illness or major surgical procedure within 1 month prior to Day 1 Uncontrolled blood pressure Glycosylated hemoglobin (HbA1c) greater than (&gt;) 10 percent (%) at screening Untreated diabetes mellitus or initiation of oral antidiabetic medication or insulin within 4 months prior to Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>